59551-02-9 Usage
General Description
5-Cyanoquinoline is a chemical compound with the molecular formula C10H6N2. It is a heterocyclic aromatic compound that consists of a quinoline ring with a cyano group attached at the 5-position. 5-Cyanoquinoline is a yellow crystalline solid that is commonly used as a building block for the synthesis of various pharmaceuticals and agrochemicals. It has been found to exhibit antibacterial and antifungal activities, making it a potential candidate for the development of new drugs. Additionally, 5-Cyanoquinoline has been used as a fluorescent probe for detecting the presence of various metal ions in biological systems. It is important to handle 5-Cyanoquinoline with care, as it is considered to be a hazardous chemical and should be used in accordance with proper safety guidelines.
Check Digit Verification of cas no
The CAS Registry Mumber 59551-02-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,9,5,5 and 1 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 59551-02:
(7*5)+(6*9)+(5*5)+(4*5)+(3*1)+(2*0)+(1*2)=139
139 % 10 = 9
So 59551-02-9 is a valid CAS Registry Number.
InChI:InChI=1/C10H6N2/c11-7-8-3-1-5-10-9(8)4-2-6-12-10/h1-6H
59551-02-9Relevant articles and documents
HETEROCYCLIC COMPOUNDS AND USES THEREOF
-
Paragraph 0324, (2021/07/31)
Provided herein are novel heterocyclic compounds, for example, compounds having Formula I, I-P, II, lI-P, or III. Also provided herein are pharmaceutical compositions comprising the compounds and methods of using the same, for example, in inhibiting aldehyde dehydrogenases and/or for treating various cancers, cancer metastasis, type 2 diabetes, pulmonary arterial hypertension (PAH) or neointimal hyperplasia (NIH).
SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
-
Paragraph 0227, (2019/10/15)
The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
